Home
PEPG
PEPG News

Latest PepGen Inc. (PEPG) News on September 9, 2025

PepGen price target lowered to $1 from $3 at BofA

TipRanks

3 months ago

PepGen price target lowered to $1 from $3 at BofA

PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target

TipRanks

3 months ago

PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target

Keros lays off nearly half its staff; Astellas buys into a China biotech’s ADC

BioPharma Dive

3 months ago

Keros lays off nearly half its staff; Astellas buys into a China biotech’s ADC

PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1

Insider Monkey

3 months ago

PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

Business Wire

3 months ago

PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

Business Wire

4 months ago

PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Business Wire

4 months ago

PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

Simply Wall St.

5 months ago

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

Business Wire

5 months ago

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference

PepGen Announces Appointment of Two New Directors to its Board

Business Wire

5 months ago

PepGen Announces Appointment of Two New Directors to its Board

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Business Wire

6 months ago

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

PepGen pauses Phase II DMD trial to review safety data

Clinical Trials Arena

6 months ago

PepGen pauses Phase II DMD trial to review safety data

MT Newswires

6 months ago

PepGen to Pause Study in Duchenne Muscular Dystrophy; Shares Down Pre-Bell

PepGen to Participate in Upcoming Investor Conferences

Business Wire

6 months ago

PepGen to Participate in Upcoming Investor Conferences

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

Business Wire

6 months ago

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

PepGen reports positive initial data from Phase I DM1 therapy trial

Clinical Trials Arena

6 months ago

PepGen reports positive initial data from Phase I DM1 therapy trial

MT Newswires

7 months ago

Top Midday Gainers

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

Business Wire

7 months ago

PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Business Wire

7 months ago

PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

PepGen price target lowered to $16 from $26 at H.C. Wainwright

TipRanks

7 months ago

PepGen price target lowered to $16 from $26 at H.C. Wainwright

PepGen Announces CONNECT Program Updates

Business Wire

7 months ago

PepGen Announces CONNECT Program Updates

All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy

Zacks

8 months ago

All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy

MT Newswires

9 months ago

Wedbush Cuts Price Target on PepGen to $8 From $12, Maintains Outperform Rating

MT Newswires

9 months ago

BofA Securities Downgrades PepGen to Underperform

MT Newswires

9 months ago

PepGen Receives FDA Clinical Hold in Trial of Potential Duchenne Muscular Dystrophy Treatment; Shares Fall

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

Business Wire

9 months ago

PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

Business Wire

10 months ago

PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Business Wire

10 months ago

PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate

Simply Wall St.

10 months ago

We're Keeping An Eye On PepGen's (NASDAQ:PEPG) Cash Burn Rate

PepGen to Participate in Upcoming Investor Conferences

Business Wire

10 months ago

PepGen to Participate in Upcoming Investor Conferences

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

Business Wire

a year ago

PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society

PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors

Business Wire

a year ago

PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development

Business Wire

a year ago

PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development

PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

Business Wire

a year ago

PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development

Is PepGen Inc. (NASDAQ:PEPG) Trading At A 34% Discount?

Simply Wall St.

a year ago

Is PepGen Inc. (NASDAQ:PEPG) Trading At A 34% Discount?

MT Newswires

a year ago

Wedbush Adjusts Price Target on PepGen to $19 From $20, Maintains Outperform Rating

MT Newswires

a year ago

Wedbush Adjusts PepGen's PT to $19 From $20, Keeps Outperform Rating

PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Business Wire

a year ago

PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)

Zacks

a year ago

Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG)

MT Newswires

a year ago

BofA Securities Downgrades PepGen to Neutral From Buy

PepGen reports positive data from Phase II Duchenne muscular dystrophy trial

Clinical Trials Arena

a year ago

PepGen reports positive data from Phase II Duchenne muscular dystrophy trial

PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Business Wire

a year ago

PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why

Zacks

a year ago

Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why

PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications

Business Wire

a year ago

PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications

MT Newswires

a year ago

PepGen Names Michelle Mellion as Chief Medical Officer

PepGen Announces Executive Team Promotions

Business Wire

a year ago

PepGen Announces Executive Team Promotions

We're Not Very Worried About PepGen's (NASDAQ:PEPG) Cash Burn Rate

Simply Wall St.

a year ago

We're Not Very Worried About PepGen's (NASDAQ:PEPG) Cash Burn Rate

MT Newswires

a year ago

PepGen Q1 Loss Narrows

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire

a year ago

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

Best Momentum Stocks to Buy for April 25th

Zacks

a year ago

Best Momentum Stocks to Buy for April 25th

PepGen to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

PepGen to Participate in Upcoming Investor Conferences

PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire

a year ago

PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?

Zacks

a year ago

Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?

PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

a year ago

PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?

PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

GlobeNewswire

2 years ago

PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire

2 years ago

PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

GlobeNewswire

2 years ago

PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock

GlobeNewswire

2 years ago

PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock

Amazon Drops $1.4 Billion iRobot Deal After EU Veto Threat

Bloomberg

2 years ago

Amazon Drops $1.4 Billion iRobot Deal After EU Veto Threat

Associated Press Finance

2 years ago

Codorus Valley: Q4 Earnings Snapshot

Codorus Valley Bancorp, Inc. Reports Fourth Quarter 2023 Results and Record Earnings for the Year

GlobeNewswire

2 years ago

Codorus Valley Bancorp, Inc. Reports Fourth Quarter 2023 Results and Record Earnings for the Year

Associated Press Finance

2 years ago

The First of Long Island: Q4 Earnings Snapshot

The First Of Long Island Corporation Reports Earnings For The Year Ended December 31, 2023

GlobeNewswire

2 years ago

The First Of Long Island Corporation Reports Earnings For The Year Ended December 31, 2023

First Bank Announces Fourth Quarter 2023 Net Income of $8.4 Million and Full Year Net Income of $20.9 Million

GlobeNewswire

2 years ago

First Bank Announces Fourth Quarter 2023 Net Income of $8.4 Million and Full Year Net Income of $20.9 Million

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

Zacks

2 years ago

Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

2 years ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

GlobeNewswire

2 years ago

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Are Investors Undervaluing First Bank (FRBA) Right Now?

Zacks

2 years ago

Are Investors Undervaluing First Bank (FRBA) Right Now?

We Like These Underlying Return On Capital Trends At Carriage Services (NYSE:CSV)

Simply Wall St.

2 years ago

We Like These Underlying Return On Capital Trends At Carriage Services (NYSE:CSV)

Institutions own 24% of PepGen Inc. (NASDAQ:PEPG) shares but private equity firms control 54% of the company

Simply Wall St.

2 years ago

Institutions own 24% of PepGen Inc. (NASDAQ:PEPG) shares but private equity firms control 54% of the company

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

Zacks

2 years ago

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

Kings River Packing Becomes First in Citrus to Implement Traceability

Business Wire

2 years ago

Kings River Packing Becomes First in Citrus to Implement Traceability

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

GlobeNewswire

2 years ago

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

Preferred Bank Announces Continuation of Share Repurchase Plan

GlobeNewswire

2 years ago

Preferred Bank Announces Continuation of Share Repurchase Plan

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

GlobeNewswire

2 years ago

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

GlobeNewswire

2 years ago

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

GlobeNewswire

2 years ago

PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

Is AdTheorent Holding Company, Inc.'s (NASDAQ:ADTH) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Simply Wall St.

2 years ago

Is AdTheorent Holding Company, Inc.'s (NASDAQ:ADTH) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Kopin to Ring Nasdaq Closing Bell on January 16th

Business Wire

2 years ago

Kopin to Ring Nasdaq Closing Bell on January 16th

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

2 years ago

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade

Investor's Business Daily

2 years ago

Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade

11 Most Promising Psychedelic Stocks According to Hedge Funds

Insider Monkey

2 years ago

11 Most Promising Psychedelic Stocks According to Hedge Funds

NaaS Technology Establishes Strategic Partnership with SHNE to Jointly Build New Energy Market

PR Newswire

2 years ago

NaaS Technology Establishes Strategic Partnership with SHNE to Jointly Build New Energy Market

Focused on COP28 and Green Practice, NaaS Technology "Takes Actions" for Achieving Carbon Neutrality in Transport Energy Sector

PR Newswire

2 years ago

Focused on COP28 and Green Practice, NaaS Technology "Takes Actions" for Achieving Carbon Neutrality in Transport Energy Sector

Camden National Corporation Announces its Fourth Quarter 2023 Dividend

PR Newswire

2 years ago

Camden National Corporation Announces its Fourth Quarter 2023 Dividend

PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

GlobeNewswire

2 years ago

PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should Know

Zacks

2 years ago

Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should Know

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire

2 years ago

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Orthofix Announces Agreement with Engine Capital and Appointment of Three New Independent Directors to Further Advance Position as Leading Global Spine and Orthopedics Company

Business Wire

2 years ago

Orthofix Announces Agreement with Engine Capital and Appointment of Three New Independent Directors to Further Advance Position as Leading Global Spine and Orthopedics Company

NewtekOne, Inc. Declares a Quarterly Dividend of $0.18 per Share

GlobeNewswire

2 years ago

NewtekOne, Inc. Declares a Quarterly Dividend of $0.18 per Share

Here's Why Momentum in Orange County Bancorp, Inc. (OBT) Should Keep going

Zacks

2 years ago

Here's Why Momentum in Orange County Bancorp, Inc. (OBT) Should Keep going

Strength Seen in Capstar Financial (CSTR): Can Its 5.4% Jump Turn into More Strength?

Zacks

2 years ago

Strength Seen in Capstar Financial (CSTR): Can Its 5.4% Jump Turn into More Strength?

We Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth Carefully

Simply Wall St.

2 years ago

We Think PepGen (NASDAQ:PEPG) Needs To Drive Business Growth Carefully

7 Short-Squeeze Stocks That Could Serve Up Serious Rewards

InvestorPlace

2 years ago

7 Short-Squeeze Stocks That Could Serve Up Serious Rewards

GlobeNewswire

2 years ago

Alpha Technology Group Limited Announces Exercise of the Underwriter’s Over-Allotment Option

Westaim Announces Closing of Skyward Specialty’s Upsized Follow-On Offering

Business Wire

2 years ago

Westaim Announces Closing of Skyward Specialty’s Upsized Follow-On Offering

The past year for Peoples Financial Services (NASDAQ:PFIS) investors has not been profitable

Simply Wall St.

2 years ago

The past year for Peoples Financial Services (NASDAQ:PFIS) investors has not been profitable

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors

GlobeNewswire

2 years ago

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors

Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023

GuruFocus.com

2 years ago

Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023

Cantaloupe, Inc. Reports First Quarter Fiscal Year 2024 Financial Results

Business Wire

2 years ago

Cantaloupe, Inc. Reports First Quarter Fiscal Year 2024 Financial Results

Share on Social Networks: